← FDA DRUG APPROVALS

FDA ANDA · ANDA065033

BLEOMYCIN SULFATE

Sponsor: TEVA PHARMS USA

APPLICATION
ANDA065033
TYPE
ANDA
ORIGINAL APPROVAL
2000-06-27
LATEST ACTION
2013-06-21
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

BLEOMYCIN SULFATEDiscontinued
BLEOMYCIN SULFATE EQ 15 UNITS BASE/VIAL · INJECTABLE · INJECTION
BLEOMYCIN SULFATEDiscontinued
BLEOMYCIN SULFATE EQ 30 UNITS BASE/VIAL · INJECTABLE · INJECTION

Approval history

2013-06-21Labeling · Supplement 23 · standardAP
2011-10-26Labeling · Supplement 17AP
2002-10-03Manufacturing (CMC) · Supplement 1AP
2000-06-27OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →